Aethlon Medical Inc (AEMD)

[mlkrborn]

Aethlon Medical Announces Collaboration to Identify Brain Trauma Biomarkers

SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has initiated a collaborative biomarker discovery program with the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine and the Sports Legacy Institute (SLI). In the collaboration, Aethlon will analyze brain tissue of professional athletes who suffered from Chronic Traumatic Encephalopathy (CTE) at the time of their death and from individuals without any evidence of brain disease. CTE is a progressive neurodegenerative disease caused by brain trauma but with unclear environmental and genetic risk factors. The research goal is to discover common biomarkers, including dormant viruses that might lead to a diagnostic product able to identify athletes with an increased susceptibility to suffer from CTE. Such a test could help distinguish those who should be precluded from participating in football and other activities with a high risk for head trauma. CTE has recently been identified in ten former NFL players, most of whom died before the age of 50 from complications of the disease, including Andre Waters, John Grimsley, Lou Creekmur, Mike Webster, and Tom McHale.